Zika Virus Vaccines by Company Profile, Deals Type, Funding, Clinical Trials Insight, Regulatory Landscape & Recent Development
It is predicted that Zika virus vaccines shot will available to the public by 2018.
Zika virus is an emerging viral disease that is transmitted through the bite of an infected mosquito, primarily Aedes aegypti, the same vector that transmits chikungunya, dengue and yellow fever. Zika has a similar epidemiology, clinical presentation and transmission cycle in urban environments as chikungunya and dengue, although it generally causes milder illness.
The highest risk is to pregnant women due to the connection the virus has with serious birth defects. Pregnant women who contract the virus have a high possibility of giving birth to a baby with microcephaly, a neurodevelopment disorder, where a baby is born with an unusually small head due to abnormal brain development in the womb or after birth. Complications of this disorder include seizures and developmental issues.
Due to the serious nature of global risk, the WHO has declared the microcephaly cases associated with the Zika virus a Public Health Emergency of International Concern (PHEIC). With no vaccines or cure the virus and its risks are expected to continue to spread. The WHO is predicting up to 4 Million Zika cases in the Americas by 2016 and the World Bank is projecting the short-term economic impact for 2016, in Latin America and the Caribbean to be about US$3.5 Billion.
With fears of Zika virus reaching new heights, Zika virus vaccines are gaining popularity. Many Government agencies and research institutes support pharmaceutical companies for the development & manufacturing of Zika virus vaccines. It is predicted that Zika virus vaccines shot will available to the public by 2018.
The research report presents a comprehensive study of the Zika virus vaccines with details. It provides essential insights of introduction of Zika virus, current situation and areas with Zika virus and funding in Zika virus vaccines research. Additionally, the report includes assessment of clinical trials and regulatory landscape of Zika virus vaccines development. Key trends in terms of partnerships, collaborations and licensing agreements are analyzed with details.
The report concludes with the profiles of major players in the Zika virus vaccines development such as Sanofi Pasteur, ImmunoVaccines Inc, Inovio Pharmaceuticals, Inc, Valneva, Bharat Biotech International Pvt. Ltd., NewLink Genetics. The major players are evaluated on various parameters such as company overview, product outlook and Zika virus vaccines latest development and trends.
This 87 Page report has been analyzed from 7 viewpoints:
1. Zika Virus – Introduction, Signs and Symptoms, Transmission, Diagnosis, Treatment & Prevention
2. Current Situation & Areas with Zika Virus
3. Competitive Landscape of The Zika Virus Vaccines Companies
4. Funding in Zika Virus Vaccines Research
5. Zika Virus Vaccines – Clinical Trials Insight by Phase & Trial Status
6. Zika Virus Vaccines – Regulatory Landscape
7. Key Companies Analysis
Zika virus is an emerging viral disease that is transmitted through the bite of an infected mosquito, primarily Aedes aegypti, the same vector that transmits chikungunya, dengue and yellow fever. Zika has a similar epidemiology, clinical presentation and transmission cycle in urban environments as chikungunya and dengue, although it generally causes milder illness.
The highest risk is to pregnant women due to the connection the virus has with serious birth defects. Pregnant women who contract the virus have a high possibility of giving birth to a baby with microcephaly, a neurodevelopment disorder, where a baby is born with an unusually small head due to abnormal brain development in the womb or after birth. Complications of this disorder include seizures and developmental issues.
Due to the serious nature of global risk, the WHO has declared the microcephaly cases associated with the Zika virus a Public Health Emergency of International Concern (PHEIC). With no vaccines or cure the virus and its risks are expected to continue to spread. The WHO is predicting up to 4 Million Zika cases in the Americas by 2016 and the World Bank is projecting the short-term economic impact for 2016, in Latin America and the Caribbean to be about US$3.5 Billion.
With fears of Zika virus reaching new heights, Zika virus vaccines are gaining popularity. Many Government agencies and research institutes support pharmaceutical companies for the development & manufacturing of Zika virus vaccines. It is predicted that Zika virus vaccines shot will available to the public by 2018.
The research report presents a comprehensive study of the Zika virus vaccines with details. It provides essential insights of introduction of Zika virus, current situation and areas with Zika virus and funding in Zika virus vaccines research. Additionally, the report includes assessment of clinical trials and regulatory landscape of Zika virus vaccines development. Key trends in terms of partnerships, collaborations and licensing agreements are analyzed with details.
The report concludes with the profiles of major players in the Zika virus vaccines development such as Sanofi Pasteur, ImmunoVaccines Inc, Inovio Pharmaceuticals, Inc, Valneva, Bharat Biotech International Pvt. Ltd., NewLink Genetics. The major players are evaluated on various parameters such as company overview, product outlook and Zika virus vaccines latest development and trends.
This 87 Page report has been analyzed from 7 viewpoints:
1. Zika Virus – Introduction, Signs and Symptoms, Transmission, Diagnosis, Treatment & Prevention
2. Current Situation & Areas with Zika Virus
3. Competitive Landscape of The Zika Virus Vaccines Companies
4. Funding in Zika Virus Vaccines Research
5. Zika Virus Vaccines – Clinical Trials Insight by Phase & Trial Status
6. Zika Virus Vaccines – Regulatory Landscape
7. Key Companies Analysis
1. EXECUTIVE SUMMARY
2. ZIKA VIRUS – INTRODUCTION, SIGNS AND SYMPTOMS, TRANSMISSION, DIAGNOSIS, TREATMENT & PREVENTION
2.1 Introduction
2.2 Signs and Symptoms
2.3 Transmission
2.4 Diagnosis
2.5 Treatment
2.6 Prevention
3. CURRENT SITUATION & AREAS WITH ZIKA VIRUS
4. COMPETITIVE LANDSCAPE OF THE ZIKA VIRUS VACCINES COMPANIES
4.1 Collaborations Deal
4.2 Partnerships & Licensing Agreements Deal
5. FUNDING IN ZIKA VIRUS VACCINES RESEARCH
6. ZIKA VIRUS VACCINES – CLINICAL TRIALS INSIGHT BY PHASE & TRIAL STATUS
6.1.1 Zika Vaccines Development: Research Gaps Identified
7. ZIKA VIRUS VACCINES – REGULATORY LANDSCAPE
7.1 Registration Process and Regulations for Vaccines in the US
7.2 Registration Process and Regulations for Vaccines in the EU
7.3 Registration Process and Regulations for Vaccines in Japan
8. KEY COMPANIES ANALYSIS
8.1 Sanofi Pasteur
8.1.1 Business Overview
8.1.2 Zika Virus Vaccines - Latest Development and Trends
8.2 ImmunoVaccines Inc.
8.2.1 Business Overview
8.2.2 Zika Virus Vaccines - Latest Development and Trends
8.3 Inovio Pharmaceuticals, Inc.
8.3.1 Business Overview
8.3.2 Inovio Pharmaceuticals, Inc.- Zika Virus Vaccines Analysis
8.3.3 Zika Virus Vaccines - Latest Development and Trends
8.4 Valneva
8.4.1 Business Overview
8.4.2 Zika Virus Vaccines - Latest Development and Trends
8.5 Bharat Biotech International Pvt. Ltd.
8.5.1 Business Overview
8.5.2 Zika Virus Vaccines - Latest Development and Trends
8.6 NewLink Genetics
8.6.1 Business Overview
8.6.2 Zika Virus Vaccines - Latest Development and Trends
2. ZIKA VIRUS – INTRODUCTION, SIGNS AND SYMPTOMS, TRANSMISSION, DIAGNOSIS, TREATMENT & PREVENTION
2.1 Introduction
2.2 Signs and Symptoms
2.3 Transmission
2.4 Diagnosis
2.5 Treatment
2.6 Prevention
3. CURRENT SITUATION & AREAS WITH ZIKA VIRUS
4. COMPETITIVE LANDSCAPE OF THE ZIKA VIRUS VACCINES COMPANIES
4.1 Collaborations Deal
4.2 Partnerships & Licensing Agreements Deal
5. FUNDING IN ZIKA VIRUS VACCINES RESEARCH
6. ZIKA VIRUS VACCINES – CLINICAL TRIALS INSIGHT BY PHASE & TRIAL STATUS
6.1.1 Zika Vaccines Development: Research Gaps Identified
7. ZIKA VIRUS VACCINES – REGULATORY LANDSCAPE
7.1 Registration Process and Regulations for Vaccines in the US
7.2 Registration Process and Regulations for Vaccines in the EU
7.3 Registration Process and Regulations for Vaccines in Japan
8. KEY COMPANIES ANALYSIS
8.1 Sanofi Pasteur
8.1.1 Business Overview
8.1.2 Zika Virus Vaccines - Latest Development and Trends
8.2 ImmunoVaccines Inc.
8.2.1 Business Overview
8.2.2 Zika Virus Vaccines - Latest Development and Trends
8.3 Inovio Pharmaceuticals, Inc.
8.3.1 Business Overview
8.3.2 Inovio Pharmaceuticals, Inc.- Zika Virus Vaccines Analysis
8.3.3 Zika Virus Vaccines - Latest Development and Trends
8.4 Valneva
8.4.1 Business Overview
8.4.2 Zika Virus Vaccines - Latest Development and Trends
8.5 Bharat Biotech International Pvt. Ltd.
8.5.1 Business Overview
8.5.2 Zika Virus Vaccines - Latest Development and Trends
8.6 NewLink Genetics
8.6.1 Business Overview
8.6.2 Zika Virus Vaccines - Latest Development and Trends
LIST OF TABLES:
Table 3 1: Countries & Territories That Have Reported Mosquito-Borne Zika Virus Transmission
Table 3 2: Countries Reporting Person-To-Person Zika Virus Transmission Since February 2016
Table 3 3: Countries & Territories That Have Reported Guillain-Barre Syndrome (GBS) Potentially Associated with Zika Virus Infection
Table 3 4: Countries & Territories That Have Reported Microcephaly and/or CNS Malformation Cases Potentially Associated with Zika Virus Infection
Table 4 1: Zika Virus Vaccines - Collaborations Deal,2016
Table 4 2: Zika Virus Vaccines - Partnerships Deal,2016
Table 4 3: Zika Virus Vaccines - Licensing Agreements,2016
Table 7 1: Japan – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
Table 3 1: Countries & Territories That Have Reported Mosquito-Borne Zika Virus Transmission
Table 3 2: Countries Reporting Person-To-Person Zika Virus Transmission Since February 2016
Table 3 3: Countries & Territories That Have Reported Guillain-Barre Syndrome (GBS) Potentially Associated with Zika Virus Infection
Table 3 4: Countries & Territories That Have Reported Microcephaly and/or CNS Malformation Cases Potentially Associated with Zika Virus Infection
Table 4 1: Zika Virus Vaccines - Collaborations Deal,2016
Table 4 2: Zika Virus Vaccines - Partnerships Deal,2016
Table 4 3: Zika Virus Vaccines - Licensing Agreements,2016
Table 7 1: Japan – Simplified Regulatory Pathway from Preclinical to the Marketing Authorization
